Eli Lilly and Company $LLY Position Lifted by Principle Wealth Partners LLC

Principle Wealth Partners LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,755 shares of the company’s stock after acquiring an additional 139 shares during the quarter. Principle Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $5,266,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Prosperity Financial Group Inc. boosted its stake in Eli Lilly and Company by 2.3% during the 2nd quarter. Prosperity Financial Group Inc. now owns 2,080 shares of the company’s stock valued at $1,622,000 after acquiring an additional 46 shares during the last quarter. Sonata Capital Group Inc. bought a new position in Eli Lilly and Company during the 2nd quarter valued at $242,000. LifeWealth Investments LLC boosted its stake in Eli Lilly and Company by 14.1% during the 2nd quarter. LifeWealth Investments LLC now owns 803 shares of the company’s stock valued at $626,000 after acquiring an additional 99 shares during the last quarter. OLD Point Trust & Financial Services N A boosted its stake in Eli Lilly and Company by 21.3% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 228 shares of the company’s stock valued at $178,000 after acquiring an additional 40 shares during the last quarter. Finally, Granite Harbor Advisors Inc. boosted its stake in Eli Lilly and Company by 2.9% during the 2nd quarter. Granite Harbor Advisors Inc. now owns 2,145 shares of the company’s stock valued at $1,672,000 after acquiring an additional 61 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 1.6%

LLY stock opened at $812.33 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The firm’s 50-day simple moving average is $762.81 and its 200 day simple moving average is $766.75. The stock has a market cap of $768.84 billion, a PE ratio of 53.09, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the company earned $3.92 EPS. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In other news, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Guggenheim reissued a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $938.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.